Acute rejection is one of the major immunological determinants of kidney graft function and survival. Early biomarkers to predict rejection are lacking. Emerging evidence reveals a crucial role for the monocyte/macrophage lineage cells in the pathogenesis of rejection. We hypothesized that higher pretransplant numbers of proinflammatory CD16+ monocytes can predict rejection. The study cohort consisted of 104 kidney transplant recipients (58 with no rejection and 46 with biopsy-proven rejection) and 33 healthy persons. Posttransplant median follow-up time was 14.7 mo (interquartile range 0.3-34 mo). Pretransplantation blood samples were analyzed by flow cytometry for monocyte immunophenotypes. Groups were compared by Cox regression models for the occurrence of acute rejection. We documented a significantly increased absolute number of pretransplant CD16+ monocytes in patients who developed biopsy-proven rejection after transplantation compared with those with no rejection (hazard ratio [HR] 1.60, 95% CI 1.28-2.00, p < 0.001) and healthy persons (HR 1.47, 95% CI 1.18-1.82, p < 0.001). In parallel, significantly fewer absolute numbers of CD16À monocytes were observed at pretransplant time points in rejectors versus nonrejectors (HR 0.74, 95% CI 0.58-0.94, p < 0,014). A higher pretransplant number of CD16+ monocytes is significantly associated with a higher risk of acute rejection after kidney transplantation.
Introduction
Extensive research on short-and long-term kidney graft fate has repeatedly shown that the occurrence of rejection, regardless of the type and timing, significantly worsens graft survival and function (1) (2) (3) . The gold standard diagnostic proof for acute rejection is renal biopsy, which is an invasive, time-consuming technique with a risk of bleeding and even graft loss (2) . At present, no clinically applicable biomarkers are available to predict rejection. Because T cells are directly involved in the pathogenesis of rejection, a large body of data on T cell-related biomarker research exists. Unfortunately, none of them have found their way to clinical practice as of yet (4) (5) (6) . The low specificity of current diagnostic factors remains a major hurdle to routine use to discriminate differential diagnostic possibilities like rejection or infection.
Recent advances in the field of molecular biology, extending from genomics to proteomics and metabolomics, have opened new possibilities to search for early rejection biomarkers in solid organ transplantation (7) (8) (9) . The mRNA encoding cytotoxic proteins like granzyme B and FOXP3 in urinary cells have been investigated extensively in prospective clinical trials (10) (11) (12) (13) (14) . Reversal of acute rejection could be predicted with 90% sensitivity and 73% specificity using urinary FOXP3 mRNA (12) . Urinary chemokines CXCL-9 and CXCL-10 were markedly elevated during acute rejection or BK infection (15, 16) . Sui et al identified 12 upregulated and eight downregulated microRNAs (miRNAs) that are differentially expressed in acute rejection compared with normal kidney tissue (17) . Anglicheau et al reported 10 upregulated miRNAs and seven downregulated miRNAs in acute rejection biopsies compared with stable kidney graft tissue (18) . Increased levels of donor-derived cellfree DNA were found during acute rejection at a very early stage (19) . Suhre et al found a composite mRNA signature consisting of 18S ribosomal RNA, CD3e mRNA, and interferon-inducible protein 10 with a specificity of 84% and a sensitivity of 90% in diagnosing acute rejection (20) . Using microarrays, a five-gene set was classified to diagnose acute rejection with 91% sensitivity and 94% specificity and needs further validation (21, 22) . A top-20 gene signature involving proliferation of B and CD4 T cells and inhibition of CD14 monocyte-related functions was shown to identify tolerant patients with almost 92% accuracy (23, 24) .
Although monocytes/macrophages were, next to T cells, recognized as early as in 1958 as the dominant cell types infiltrating acutely rejecting grafts, biomarker research in this area has lagged (25) . The heterogeneity and plasticity of the monocyte/macrophage/dendritic cell lineage have been obstacles to translating the functional relevance to diagnostic and prognostic clinical biomarkers. A new approach is to focus on the monocyte/macrophage lineage cells as emerging evidence reveals a crucial role for this cell line in the pathogenesis of rejection associated with worse outcome (26) (27) (28) . Monocyte/macrophage lineage cells have a number of roles in the rejection process: immune regulation, antigen processing and presentation, inflammation, cytotoxicity, phagocytosis, response to injury, and tissue remodeling (29) (30) (31) . Glomerular and peritubular monocyte infiltration in acute rejection kidney biopsies could predict worse graft outcome (32) (33) (34) . In another study, increased infiltration of an activated population of macrophages could discriminate between clinical and subclinical kidney transplant rejection (35) . Furthermore, monocyte infiltration has been positively associated with the degree of kidney transplant dysfunction (36) . Circulating monocyte subsets can be characterized as classical (CD14++CD16À), intermediate (CD14++CD16+), and nonclassical (CD14+CD16++). CD16+ monocytes are known to produce high amounts of TNF-a and IL-1b and thus are considered highly proinflammatory (37) (38) (39) . CD16+ monocytes have unique functions in angiogenesis, production of reactive oxygen species, and patrolling behavior (37, (40) (41) (42) . Moreover, the intermediate CD16+ monocytes have been associated with the development of atherosclerosis in patients with chronic kidney disease (43) (44) (45) (46) .
We hypothesized that there are essential differences in pretransplant monocyte subset composition between patients with allograft rejection and with no rejection, in particular with regard to pretransplant proinflammatory CD16+ monocyte numbers. In that case, pretransplant numbers of CD16+ monocytes could serve as an early biomarker for acute rejection after kidney transplantation. To this end, we investigated the pretransplant monocyte immunophenotypes in a study cohort consisting of 104 kidney transplant recipients. Of the included patients, 58 developed biopsy-proven rejection within the first 24 months after transplantation, and 46 patients remained free of any rejection episodes with a median follow-up time of 14.7 mo (interquartile range [IQR] 0.3-34 mo). Overall, 33 healthy persons served as controls.
Methods

Population information
In total, 104 patients who had undergone renal transplantation between 2007 and 2012 were studied. This cohort concerns a selection of patients with available blood samples who underwent ABO-and HLA-compatible kidney transplantations. Peripheral blood mononuclear cells (PBMCs) were isolated from heparinized blood using Ficoll-Hypaque density gradient (Lymphoprep, STEMCELL Technologies, Kö ln, Germany) and stored at À150°C until analysis. From this cohort, 58 patients were selected who remained free of rejection and 46 patients were selected who developed biopsy-proven acute rejection. In addition, 33 healthy persons served as controls. Furthermore, we performed a pilot case-control study to investigate monocyte subset composition in blood and to relate these findings to the same variables at tissue level in case of acute rejection compared with six patients with stable graft function who served as control. To this end, the peripheral blood mononuclear cells were serially obtained from six rejecting kidney transplant recipients at the time of transplantation and at the time of biopsy-proven acute rejection (T cell-mediated rejection type IA). Six stable kidney transplant recipients served as controls, with blood samples obtained at exactly the same corresponding time points. Table 1 lists the transplantation characteristics and the clinical and immunological features of the whole cohort and patients participating in the pilot case-control study. Overall, 20% of the group with no acute rejection and 13% of the rejection group received basiliximab induction therapy No induction treatment was given in the other cases. All patients received the same maintenance immunosuppressive regimen, consisting of a calcineurin inhibitor, tacrolimus (Prograft, Astellas Pharma B.V. Leiderdorp, the Netherlands), mycophenolate mofetil (CellCept, Roche, the Netherlands), and prednisolone (Merckle GmbH, Blaubeuren, Germany). Prednisolone was tapered to zero according to local standard protocol during the first 4 mo after transplantation if no rejection was detected. Delayed graft function after transplantation was defined as the need for continuing dialysis due to insufficient kidney transplant function. Rejection was diagnosed by for-cause biopsies. No rejection was defined by stable transplant function. We do not perform protocol biopsies at our center. Biopsy-proven acute rejection was defined according to the Banff criteria 2015. Serum samples from recipients were screened for the presence or absence of HLA antibodies using the Lifecodes Lifescreen Deluxe kit, according to the manufacturer's manual (Immunocor Transplant Diagnostics Inc., Stamford, CT). Samples that were considered positive for either HLA class I (HLA-A, -B, or -C) or HLA class II (HLA-DQ or -DR) antibodies were further analyzed with a Luminex single antigen assay using LABScreen HLA class I and class II antigen beads (One Lambda, Canoga Park, GA). Samples were measured using a Luminex 100 reader (Luminex Corporation, 's-Hertogenbosch, the Netherlands), and the baseline normalized values were used. LABScreen-negative control serum (One Lambda, Inc, Canoga Park, CA) was used as a negative control. All patients signed written informed consent. The medical ethics committee approved the study 
Monocyte phenotype
Monocytes were identified based on forward/sideward scatter, lack of expression of CD3, and lack of expression of CD20 and CD56. Subsequently, they were characterized by the expression of CD14 and CD16, as described previously ( Figure S1 ) (47) . Because only frozen blood samples were available for this study, the absolute numbers of the monocyte subset population were determined using the absolute number of monocytes measured in whole blood, recalculated to the percentages measured in fluorescence-activated cell sorting analysis.
CD14 and CD16 double immunofluorescence stainings of rejection biopsies
Immunofluorescence stainings were performed using double indirect labeling. In brief, following fixation with acetone, slides were blocked with normal goat serum 10% (Jackson ImmunoResearch Laboratories, Inc., West Grove, PA). Primary mouse-monoclonal CD14 IgG2a antibody was incubated overnight at 4°C. Secondary goat antimouse IgG2a Alexa Fluor 488 (Invitrogen, Waltham, MA) was applied for 1 h at room temperature (RT). To minimize nonspecific binding, goat antimouse Fab fragment (Jackson ImmunoResearch) was applied for 30 min at RT. After washing steps, the second primary antibody, mouse monoclonal CD16 IgG1, was added for 1 h. Next, the secondary goat antimouse IgG1 Alexa Fluor 555 (Invitrogen) was applied for another 1 h at RT. Following washing steps, the slides were covered with antifading mounting medium containing DAPI (4 0 ,6-diamidino-2-phenylindole; Vectashield, UK) and stored at 4°C until evaluation.
Confocal microscopy was performed using an LSM-700 laser scanning confocal microscope (Carl Zeiss, Oberkochen, Germany). All biopsy samples (size range 4-5 cm) were evaluated for presence of CD14+CD16À, CD14+CD16+, or CD14-CD16+ cells using 940 magnification.
Statistical analysis
Differences between means were analyzed using the Student t-test or Mann-Whitney U test, as appropriate. Both univariate and multivariate analyses were performed to study the relation between the absolute numbers of different monocyte immunophenotypes at the pretransplant 
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Results
Kidney transplant recipient characteristics
The clinical and immunological characteristics of the kidney transplant recipients are shown in Table 1 . Posttransplant median follow-up time was 14.7 mo (IQR 0.3-34 mo). The median age was 50 years for the group with no rejection and 53 years for the group with rejection. Overall, 77% received living donor kidneys, whereas in the rejector group, 82% of kidneys were from living donors (p = 0.87). Total numbers of HLA mismatches were not different between groups (p = 0.52). The groups showed no significant difference in the numbers of previous transplantations (p = 0.05). No statistically significant difference was noted with regard to the occurrence of delayed graft function between two groups (p = 0.07). Historical peak percentage of PRA was significantly higher in rejectors (p = 0.01). All observed acute rejection episodes occurred within the first 24 mo after transplantation, with the majority of rejection incidence within the first year after transplant (44 of 46). Rejection was classified according to the latest Banff 2015 classification (Table S1 .). Patients with loss of graft function were returned to dialysis (p = 0.03).
High pretransplant numbers of CD16+ monocytes are associated with biopsy-proven acute rejection At pretransplantation, significantly higher absolute numbers ( Figure 1A ) and percentages ( Figure 1B ) of both intermediate CD14++CD16+ and nonclassical CD14+CD16++ monocyte subsets were detected in the rejector group compared with nonrejectors and healthy persons (p < 0.05). Concordantly, the absolute numbers of classical (CD14++CD16À) monocytes were significantly lower in rejectors compared with nonrejectors (p < 0.001) and healthy controls (p < 0.01). These findings may refer to a higher proinflammatory set point in the monocytic system at a pretransplant time point in kidney transplant recipients who develop acute rejection after transplantation and during follow-up. Higher absolute pretransplant numbers of CD16+ monocytes are associated with shorter rejection-free survival, whereas higher absolute numbers of classical monocytes are associated with longer rejection-free survival Kaplan-Meier acute rejection-free survival curves were extracted for tertiles of classical (Figure 2A ), intermediate ( Figure 2B ), and nonclassical monocytes ( Figure 2C ). Differences between survival curves were analyzed using the log-rank test between the highest and the lowest tertiles. A higher cumulative incidence of rejection was associated with the lowest tertile of absolute numbers of classical monocytes in a pretransplant patient's sample, whereas higher tertiles were associated with a lower rejection risk (v 2 = 6.1, p < 0.05). In contrast, higher tertiles of absolute numbers of both intermediate (v 2 = 9.6, p < 0.01) and nonclassical (v 2 = 6.4, p < 0.05) CD16+ monocytes in pretransplant patient samples were associated with significantly higher rejection risk.
Transplant tissue infiltration by CD16+ monocytes at rejection, a pilot case-control study We studied subset composition of circulating monocytes in patients experiencing biopsy-proven acute cellular rejection at two time points, namely, at the time of transplantation and at the time of biopsy (before start of treatment). As controls, blood samples were obtained from age-and sex-matched nonrejecting stable patients at the same corresponding time points. Figure 3A shows a representative demonstration of monocyte subsets in patients with rejection (n = 6) and patients with no rejection (n = 6) at pretransplantation and rejection-matched time points. In the group with no rejection, no numerical differences were detected in monocyte subsets between these two time points; however, in the group with rejection, the CD16+ monocytes were significantly increased in pretransplant specimens compared with monocytes from patients with no rejection. Intriguingly, frequencies of CD16+ monocytes were significantly decreased in peripheral blood at the time of rejection (p < 0.05), pointing toward the possibility of migration of proinflammatory CD16+ monocytes to the rejecting kidney. In line, extensive tubulointerstitial infiltration of CD14+CD16+ monocytes was detected in graft tissue during rejection ( Figure 3B ). . Differences between survival curves were analyzed using the log-rank test between the highest and the lowest tertiles.
Discussion
A major clinical challenge is the lack of biomarkers to predict rejection in kidney transplantation. In this study, we assessed whether pretransplant numbers of proinflammatory CD16+ monocytes could predict acute rejection risk after kidney transplantation. We found that patients who developed acute rejection after transplantation possessed higher absolute numbers of CD16+ monocytes at the time of transplantation compared with patients with no rejection. Alternatively, high numbers of classical monocytes before transplant were significantly associated with lower rejection risk. In a pilot case-control study, we showed abundant accumulation of CD16+ monocytes at rejection in kidney graft tissue, with a concomitant decrease of the absolute number of circulating CD16+ monocytes in peripheral blood. These findings indicate a migratory shift of CD16+ monocytes from the circulation toward the rejecting tissue.
Monocytes/macrophages have shown their potential value as biomarkers in several diseases (26, 31, (48) (49) (50) (51) (52) . Recently, we documented a skewed shift toward proinflammatory CD16+ monocytes in stable kidney transplant recipients that was already present at the time of transplantation and was retained during the first 6 mo after transplant despite immunosuppressive therapy and a significant improvement in kidney function (47) . These monocytes were capable of interferon c production (53) . Many studies have tried to identify the type and function of injury-related monocytes in kidney transplant recipients and in patients with chronic renal failure undergoing dialysis. CD163 overexpression on circulating monocytes was shown to be useful in prediction of transplant function after kidney transplantation. CD163 overexpression seemed to significantly correlate with serum creatinine values 1 year after transplantation (54) . This subpopulation is involved in regulating the production of antiinflammatory cytokines by macrophages. Recently, graft infiltration by CD16+ monocytes with smooth muscle cell-like characteristics was documented during chronic transplant dysfunction, which suggests tissue remodeling including neointima formation in transplant arteries and formation of a profibrotic matrix via TGF-b expression (55) . Patients with chronic renal failure undergoing dialysis have been shown to possess expanded CD14+CD16+ monocyte pools with production of proinflammatory cytokines like IL-1b, tumor necrosis factor a, and IL-6 (56, 57) . Other studies showed that hemodialysis leads to temporary removal of monocytes in the peripheral blood followed by the reappearance of activated CD14+CD16+ monocytes (58) . Although more detailed knowledge is now available with regard to phenotype and function of different subtypes of monocytes, no information regarding the molecular signature and functional roles of the monocyte subsets in relation to distinct acute and chronic rejection types is known as yet. Advances in genomics and proteomics will help answer these open questions; define the nature of the monocyte subset in the context of disease; and move the diagnostic, prognostic, and therapeutic biomarker discovery field forward.
This report describes a proof-of-principle study indicating the feasibility of CD16+ monocytes pretransplant number as a predictive marker for rejection. We reported on a novel concept of the (CD16+) monocyte as a crucial immune cell type participating in the pathogenesis of rejection and showing measurable subset differences before transplantation between patients who will develop rejection and patients who will remain free of rejection. Interestingly, at the time of rejection, a measurable decrease in circulating CD16+ monocyte subset was paralleled by an increase in tissue-infiltrating CD16+ monocytes, implying a migration toward inflamed graft. These results should be confirmed in a larger prospective blinded validation fashion, as there are limitations and cautions. The studied population was selected based on available blood samples. Although almost equally distributed, part of the study population (four of five [80%] of the no-rejection group and eight of 11 (72%) of the rejection group) was retransplanted, had a graft in situ, and used immunosuppressive medication. All of these parameters could have an effect on circulating monocyte subsets and numbers, which need to be taken into account in a future validation study. Next, we want to investigate the specificity of this finding by including more diagnostic groups in the future, such as patients with BK nephropathy, delayed graft function, cytomegalovirus infection, and urinary tract infections. Altogether, our data show that higher pretransplant numbers of CD16+ monocytes are associated with significantly higher rejection risk and shorter rejection-free survival and may serve as an early biomarker to predict acute rejection after kidney transplantation. A calculated cutoff value of 23.5/lL CD16+ monocyte numbers before transplant could have a sensitivity of 90% to detect the population at risk for rejection. Conversely, higher numbers of CD14+CD16À monocytes are significantly associated with a no-rejection outcome. Interestingly, the absolute numbers of CD14+ monocytes can be measured using CD14+ beads offering a simple, cheap, and fast immunological monitoring tool for future validation studies.
Next-step research is warranted to investigate the value of monocyte subset monitoring in risk stratification and personalized optimization of immunosuppressive treatment as a cornerstone of posttransplant clinical work-up of kidney transplant recipients.
Acknowledgments
This work is supported by Erasmus Medical University fellowship award to A.T. Rowshani, MD, PhD (Project number: 102178).
Author Contributions
TPP contributed in the process of design/experimenting/ discussing/results/data analysis/writing, LBH contributed in the process of sample collection and writing/reviewing, RK contributed in the process of experimenting, NHRL contributed in the process of sample collection and writing/reviewing, FR contributed in design/discussing results and and writing/reviewing, DN contributed in the process of data analysis and and writing/reviewing, EWS contributed in the process of data analysis and writing/ reviewing, JAG contributed in the process of sample collection and writing/reviewing, DLR contributed in the process of experimenting and writing/reviewing, MCG contributed in experimenting, writing and reviewing, CCB contributed in the process of sample collection and writing/ reviewing and ATR contributed in the process of design/ experimenting/discussing results/data analysis/writing.
Disclosure Supporting Information
Additional Supporting Information may be found in the online version of this article. Figure S1 : Gating strategy for monocytes. Representative fluorescence-activated cell sorting plots for the gating strategy at pretransplant time point to determine monocyte subset populations: CD3, CD20, and CD56 negative and CD14 and CD16 positive. Monocytes were characterized based on forward/sideward scatter, lack of expression of CD3, followed by lack of expression of CD20 and CD56, and then selected by positive expression of CD14 and CD16. 
